Close Menu

PD-L1 Biomarkers

News and reporting on PD-L1 biomarkers.

The studies highlighted the activity of three drugs in NSCLC patients characterized by HER2 mutations, CECAM5 overexpression, and high PD-L1 expression.

In another study at ASCO, the immunotherapy showed benefits as maintenance therapy in advanced bladder cancer patients, regardless of PD-L1 expression status.

Bristol Myers Squibb is hoping that the durable responses seen with the combined immunotherapy drugs will convince doctors to prescribe it for their patients.

The latest approval is immunotherapy Tecentriq's fourth indication in non-small cell lung cancer and fifth indication in lung cancer.

This approval, based on the part 1a results from the Phase III CheckMate-227 trial, is the fifth indication for this drug combination.

In KEYNOTE-355, patients with PD-L1 expression greater than or equal to a combined positive score of 10 had improved progression-free survival on first-line Keytruda and chemo.

WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.

The data from the trial will support regulatory submissions in the US and EU for Libtayo as a first-line option for PD-L1 positive non-small cell lung cancer patients.

This is the second approval for tislelizumab following the drug's initial approval in classical Hodgkin's lymphoma last year.

Pembrolizumab provided long-term overall survival benefit in second-line treatment and can be effectively used for retreatment after disease progression.

Pages